{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:18:17Z","timestamp":1784557097729,"version":"3.55.0"},"reference-count":42,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study aimed to describe real-world patient and physician characteristics, rearranged during transfection (\n                      <jats:italic>RET<\/jats:italic>\n                      ) mutation testing and results, treatment patterns and patient-reported outcomes (PROs) in advanced or metastatic medullary thyroid cancer (aMTC) across five populous European countries.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cross-sectional physician and patient surveys were used to collect quantitative and qualitative data in France, Germany, Italy, Spain and the UK from July to December 2020, prior to the introduction of selective RET inhibitors in Europe. Physicians completed patient record forms and a survey about their specialty and practice site. Patients were asked to provide PRO data using four validated instruments, including the EuroQol 5 Dimension (EQ-5D) questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The physician-reported sample included 275 patients with aMTC, including 79 patients with\n                      <jats:italic>RET<\/jats:italic>\n                      mutation-positive disease; median age was 60 and 56 years, respectively. Overall, 75% were tested for\n                      <jats:italic>RET<\/jats:italic>\n                      mutation (35% germline only, 21% somatic only and 44% both). Common physician-cited barriers to\n                      <jats:italic>RET<\/jats:italic>\n                      mutation testing included high cost, difficulty accessing the latest tests and time delay for results. First-line systemic therapy (most commonly vandetanib or cabozantinib) was prescribed for 69% of patients overall and 82% of the\n                      <jats:italic>RET<\/jats:italic>\n                      mutation-positive subgroup. Second-line therapy was prescribed for 12% of patients who received first-line therapy; most patients remained on first-line therapy at data capture. PROs revealed a substantial disease\/treatment burden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Patients with aMTC report a substantial disease\/treatment burden. Outcomes could be improved by identifying patients eligible for treatment with selective RET inhibitors through more optimal\n                      <jats:italic>RET<\/jats:italic>\n                      mutation testing.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-23-0172","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T10:00:26Z","timestamp":1704708026000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":4,"title":["Real-world clinical profile, RET mutation testing, treatments and patient-related outcomes for medullary thyroid cancer in Europe"],"prefix":"10.1530","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-7633","authenticated-orcid":true,"given":"Grace","family":"Segall","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6484-1365","authenticated-orcid":true,"given":"Ravinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hua","family":"Jen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Sanderson","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-002X","authenticated-orcid":true,"given":"Alex","family":"Rider","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-7587","authenticated-orcid":true,"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-940X","authenticated-orcid":true,"given":"Urpo","family":"Kiiskinen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"New England Journal of Medicine","first-page":"437","article-title":"C-cell hyperplasia preceding medullary thyroid carcinoma","volume":"289","author":"Wolfe","year":"1973","unstructured":"Wolfe HJMelvin KECervi-Skinner SJSaadi AAJuliar JFJackson CE & Tashjian AHJr. C-cell hyperplasia preceding medullary thyroid carcinoma. New England Journal of Medicine1973289437\u2013441. (https:\/\/doi.org\/10.1056\/NEJM197308302890901)"},{"key":"bib2","series-title":"Endocrine-Related Cancer","first-page":"R499","article-title":"Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives","volume":"26","author":"Ceolin","year":"2019","unstructured":"Ceolin LDuval MADSBenini AFFerreira CV & Maia AL. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocrine-Related Cancer201926R499\u2013R518. (https:\/\/doi.org\/10.1530\/ERC-18-0574)"},{"key":"bib3","series-title":"Lancet. Diabetes and Endocrinology","first-page":"225","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho","year":"2021","unstructured":"Miranda-Filho ALortet-Tieulent JBray FCao BFranceschi SVaccarella S & Dal Maso L. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet. Diabetes and Endocrinology20219225\u2013234. (https:\/\/doi.org\/10.1016\/S2213-8587(2100027-9)"},{"key":"bib4","article-title":"Medullary thyroid cancer","unstructured":"National Cancer Institute. Medullary thyroid cancer. Available at: https:\/\/www.cancer.gov\/pediatric-adult-rare-tumor\/rare-tumors\/rare-endocrine-tumor\/medullary-thyroid-cancer#):~:text=How%20common%20is%20medullary%20thyroid,each%20year%20in%20the%20U.S (Accessed 11 November 2022)."},{"key":"bib5","series-title":"Nature Reviews. Endocrinology","first-page":"192","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","unstructured":"Romei CCiampi R & Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nature Reviews. Endocrinology201612192\u2013202. (https:\/\/doi.org\/10.1038\/nrendo.2016.11)"},{"key":"bib6","series-title":"Cancers","first-page":"3643","article-title":"Update on the diagnosis and management of medullary thyroid cancer: what has changed in recent years?","volume":"14","author":"Kaliszewski","year":"2022","unstructured":"Kaliszewski KLudwig MLudwig BMiku\u0142a AGreniuk M & Rudnicki J. Update on the diagnosis and management of medullary thyroid cancer: what has changed in recent years?Cancers2022143643. (https:\/\/doi.org\/10.3390\/cancers14153643)"},{"issue":"Supplement 1","key":"bib7","series-title":"International Journal of Surgery","first-page":"S2","article-title":"Genetics of medullary thyroid cancer: an overview","volume":"41","author":"Accardo","year":"2017","unstructured":"Accardo GConzo GEsposito DGambardella CMazzella MCastaldo FDi Donna CPolistena AAvenia NColantuoni V, et al.Genetics of medullary thyroid cancer: an overview. International Journal of Surgery201741(Supplement 1) S2\u2013S6. (https:\/\/doi.org\/10.1016\/j.ijsu.2017.02.064)"},{"key":"bib8","series-title":"Current Oncology","first-page":"389","article-title":"A primer on the genetics of medullary thyroid cancer","volume":"26","author":"Larouche","year":"2019","unstructured":"Larouche VAkirov AThomas CMKrzyzanowska MK & Ezzat S. A primer on the genetics of medullary thyroid cancer. Current Oncology201926389\u2013394. (https:\/\/doi.org\/10.3747\/co.26.5553)"},{"key":"bib9","series-title":"iScience","first-page":"324","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","unstructured":"Ciampi RRomei CRamone TPrete ATacito ACappagli VBottici VViola DTorregrossa LUgolini C, et al.Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience201920324\u2013336. (https:\/\/doi.org\/10.1016\/j.isci.2019.09.030)"},{"key":"bib10","series-title":"Genes","first-page":"698","article-title":"Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations","volume":"10","author":"Elisei","year":"2019","unstructured":"Elisei RTacito ARamone TCiampi RBottici VCappagli VViola DMatrone ALorusso LValerio L, et al.Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations. Genes201910698. (https:\/\/doi.org\/10.3390\/genes10090698)"},{"key":"bib11","series-title":"Nature Reviews. Endocrinology","first-page":"296","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","unstructured":"Salvatore DSantoro M & Schlumberger M. The importance of the RET gene in thyroid cancer and therapeutic implications. Nature Reviews. Endocrinology202117296\u2013306. (https:\/\/doi.org\/10.1038\/s41574-021-00470-9)"},{"key":"bib12","series-title":"Annals of Oncology","first-page":"674","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","unstructured":"Filetti SDurante CHartl DMLeboulleux SLocati LDNewbold KPapotti MGBerruti A & ESMO Guidelines Committee.ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Annals of Oncology202233674\u2013684. (https:\/\/doi.org\/10.1016\/j.annonc.2022.04.009)"},{"key":"bib13","series-title":"NCCN Guidelines for Thyroid Carcinoma","year":"2022","unstructured":"NCCN. NCCN Guidelines for Thyroid Carcinoma, Version 2.20222022. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1470 (Accessed 15 November 2022)."},{"key":"bib14","article-title":"Selpercatinib (Retsevmo\u00ae) summary of product characteristics","unstructured":"Selpercatinib (Retsevmo\u00ae) summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/retsevmo-epar-product-information_en.pdf (Accessed 7 December 2022)."},{"key":"bib15","article-title":"Pralsetinib (Gavreto\u00ae) summary of product characteristics","unstructured":"Pralsetinib (Gavreto\u00ae) summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gavreto-epar-product-information_en.pdf (Accessed 7 December 2022)."},{"key":"bib16","series-title":"British Journal of Cancer","first-page":"1777","article-title":"Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas","volume":"100","author":"Moura","year":"2009","unstructured":"Moura MMCavaco BMPinto AEDomingues RSantos JRCid MOBugalho MJ & Leite V. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. British Journal of Cancer20091001777\u20131783. (https:\/\/doi.org\/10.1038\/sj.bjc.6605056)"},{"key":"bib17","series-title":"Thyroid Research","first-page":"2","article-title":"Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced\/metastatic medullary thyroid cancer","volume":"15","author":"Parikh","year":"2022","unstructured":"Parikh RHess LMEsterberg EBhandari NR & Kay JA. Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced\/metastatic medullary thyroid cancer. Thyroid Research2022152. (https:\/\/doi.org\/10.1186\/s13044-021-00119-9)"},{"key":"bib18","series-title":"Surgery","first-page":"137","article-title":"Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years","volume":"161","author":"Randle","year":"2017","unstructured":"Randle RWBalentine CJLeverson GEHavlena JASippel RSSchneider DF & Pitt SC. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery2017161137\u2013146. (https:\/\/doi.org\/10.1016\/j.surg.2016.04.053)"},{"key":"bib19","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2807","article-title":"Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness","volume":"102","author":"Voss","year":"2017","unstructured":"Voss RKFeng LLee JEPerrier NDGraham PHHyde SMNieves-Munoz FCabanillas MEWaguespack SGCote GJ, et al.Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness. Journal of Clinical Endocrinology and Metabolism20171022807\u20132813. (https:\/\/doi.org\/10.1210\/jc.2017-00317)"},{"key":"bib20","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3591","article-title":"Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma","volume":"102","author":"Cote","year":"2017","unstructured":"Cote GJEvers CHu MIGrubbs EGWilliams MDHai TDuose DYHouston MRBui JHMehrotra M, et al.Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism20171023591\u20133599. (https:\/\/doi.org\/10.1210\/jc.2017-01039)"},{"key":"bib21","series-title":"Thyroid","first-page":"459","article-title":"Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer","volume":"31","author":"Koehler","year":"2021","unstructured":"Koehler VFAdam PFrank-Raue KRaue FBerg EHoster EAllelein SSchott MKroiss M & Spitzweg C. Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer. Thyroid202131459\u2013469. (https:\/\/doi.org\/10.1089\/thy.2020.0206)"},{"key":"bib22","series-title":"Current Medical Research and Opinion","first-page":"3063","article-title":"Real-world physician and patient behaviour across countries: disease-Specific Programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","unstructured":"Anderson PBenford MHarris NKaravali M & Piercy J. Real-world physician and patient behaviour across countries: disease-Specific Programmes - a means to understand. Current Medical Research and Opinion2008243063\u20133072. (https:\/\/doi.org\/10.1185\/03007990802457040)"},{"key":"bib23","series-title":"Health and Quality of Life Outcomes","first-page":"94","article-title":"Correspondence between EQ-5D health state classifications and EQ VAS scores","volume":"6","author":"Whynes","year":"2008","unstructured":"Whynes DK & TOMBOLA Group. Correspondence between EQ-5D health state classifications and EQ VAS scores. Health and Quality of Life Outcomes2008694. (https:\/\/doi.org\/10.1186\/1477-7525-6-94)"},{"key":"bib24","article-title":"EQ-5D-3L user guide","unstructured":"EuroQol Research Foundation. EQ-5D-3L user guide. Available at: https:\/\/euroqol.org\/publications\/user-guides (Accessed 12 November 2022)"},{"key":"bib25","series-title":"Leukemia and Lymphoma","first-page":"290","article-title":"The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma","volume":"54","author":"Yost","year":"2013","unstructured":"Yost KJThompson CAEton DTAllmer CEhlers SLHabermann TMShanafelt TDMaurer MJSlager SLLink BK, et al.The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma201354290\u2013297. (https:\/\/doi.org\/10.3109\/10428194.2012.711830)"},{"key":"bib26","series-title":"Pharmacoeconomics","first-page":"353","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","unstructured":"Reilly MCZbrozek AS & Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics19934353\u2013365. (https:\/\/doi.org\/10.2165\/00019053-199304050-00006)"},{"key":"bib27","series-title":"BMJ Open","first-page":"e010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme","volume":"6","author":"Babineaux","year":"2016","unstructured":"Babineaux SMCurtis BHolbrook TMilligan G & Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open20166e010352. (https:\/\/doi.org\/10.1136\/bmjopen-2015-010352)"},{"key":"bib28","series-title":"Diabetes, Metabolic Syndrome and Obesity","first-page":"371","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","unstructured":"Higgins VPiercy JRoughley AMilligan GLeith ASiddall J & Benford M. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes, Metabolic Syndrome and Obesity20169371\u2013380. (https:\/\/doi.org\/10.2147\/DMSO.S120101)"},{"key":"bib29","article-title":"Association (EphMRA) code of conduct","unstructured":"European Pharmaceutical Market Research. Association (EphMRA) code of conduct. Available at: https:\/\/www.ephmra.org\/standards\/code-of-conduct\/ (Accessed: 7 December 2022)."},{"key":"bib30","series-title":"Health Information Technology Act","article-title":"Health information technology","unstructured":"Health information technology. Health Information Technology Act. Available at: https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf. (Accessed: 7 December 2022)."},{"key":"bib31","series-title":"Health and Quality of Life Outcomes","first-page":"70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","unstructured":"Pickard ASNeary MP & Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes2007570. Erratum in: Health and Quality of Life Outcomes201084. (https:\/\/doi.org\/10.1186\/1477-7525-5-70)"},{"key":"bib32","series-title":"Journal of Clinical Epidemiology","first-page":"898","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","unstructured":"Eton DTCella DYost KJYount SEPeterman AHNeuberg DSSledge GW & Wood WC. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. Journal of Clinical Epidemiology200457898\u2013910. (https:\/\/doi.org\/10.1016\/j.jclinepi.2004.01.012)"},{"key":"bib33","series-title":"Annals of Oncology","first-page":"1856","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","unstructured":"Filetti SDurante CHartl DLeboulleux SLocati LDNewbold KPapotti MGBerruti A & ESMO Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Annals of Oncology2019301856\u20131883. (https:\/\/doi.org\/10.1093\/annonc\/mdz400)"},{"key":"bib34","article-title":"Real-world study of Rearranged during Transfection [RET] testing in patients with medullary thyroid cancer [MTC] in Europe [EU5]","author":"Williams","year":"2021","unstructured":"Williams RHess LMPuri TJen M-HKostikas MRider A & Kiiskinen U. Real-world study of Rearranged during Transfection [RET] testing in patients with medullary thyroid cancer [MTC] in Europe [EU5]. Poster 1751P presented at the European Society for Medical Oncology (ESMO) 46th Congress; Virtual2021. (https:\/\/doi.org\/10.1016\/j.annonc.2021.08.897)"},{"key":"bib35","series-title":"European Journal of Health Economics","first-page":"205","article-title":"Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries","volume":"20","author":"Janssen","year":"2019","unstructured":"Janssen MFSzende ACabases JRamos-Go\u00f1i JMVilagut G & K\u00f6nig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. European Journal of Health Economics201920205\u2013216. (https:\/\/doi.org\/10.1007\/s10198-018-0955-5)"},{"key":"bib36","series-title":"Quality of Life Research","first-page":"2337","article-title":"Validity of the EQ-5D-5L and reference norms for the Spanish population","volume":"27","author":"Hernandez","year":"2018","unstructured":"Hernandez GGarin OPardo YVilagut GPont \u00c0Su\u00e1rez MNeira MRajmil LGorostiza IRamallo-Fari\u00f1a Y, et al.Validity of the EQ-5D-5L and reference norms for the Spanish population. Quality of Life Research2018272337\u20132348. (https:\/\/doi.org\/10.1007\/s11136-018-1877-5)"},{"key":"bib37","series-title":"Quality of Life Research","first-page":"527","article-title":"Belgian population norms for the EQ-5D-5L, 2018","volume":"31","author":"Van Wilder","year":"2022","unstructured":"Van Wilder LCharafeddine RBeutels PBruyndonckx RCleemput IDemarest SDe Smedt DHens NScohy ASpeybroeck N, et al.Belgian population norms for the EQ-5D-5L, 2018. Quality of Life Research202231527\u2013537. (https:\/\/doi.org\/10.1007\/s11136-021-02971-6)"},{"key":"bib38","series-title":"International Journal of Surgery","first-page":"133","article-title":"Quality of life in differentiated thyroid cancer","volume":"50","author":"McIntyre","year":"2018","unstructured":"McIntyre CJacques TPalazzo FFarnell K & Tolley N. Quality of life in differentiated thyroid cancer. International Journal of Surgery201850133\u2013136. (https:\/\/doi.org\/10.1016\/j.ijsu.2017.12.014)"},{"key":"bib39","series-title":"Cancer","first-page":"2902","article-title":"Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy","volume":"120","author":"Pearman","year":"2014","unstructured":"Pearman TYanez BPeipert JWortman KBeaumont J & Cella D. Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer20141202902\u20132909. (https:\/\/doi.org\/10.1002\/cncr.28758)"},{"key":"bib40","series-title":"Health and Quality of Life Outcomes","first-page":"172","article-title":"Health-related quality of life (FACT-GP) in Sweden","volume":"18","author":"Lindqvist Bagge","year":"2020","unstructured":"Lindqvist Bagge ASCarlander AFahlke C & Olofsson Bagge R. Health-related quality of life (FACT-GP) in Sweden. Health and Quality of Life Outcomes202018172. (https:\/\/doi.org\/10.1186\/s12955-020-01420-1)"},{"key":"bib41","series-title":"Advances in Therapy","first-page":"3850","article-title":"Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan","volume":"37","author":"Takahashi","year":"2020","unstructured":"Takahashi STahara MIto KTori MKiyota NYoshida KSakata Y & Yoshida A. Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Advances in Therapy2020373850\u20133862. Erratum in: Advances in Therapy2021384989\u20134993. (https:\/\/doi.org\/10.1007\/s12325-021-01829-0)"},{"key":"bib42","series-title":"Endocrinology and Metabolism","first-page":"587","article-title":"Vandetanib for the management of advanced medullary thyroid cancer: a real-world multicenter experience","volume":"35","author":"Kim","year":"2020","unstructured":"Kim MYoon JHAhn JJeon MJKim HKLim DJKang HCKim IJShong YKKim TY, et al.Vandetanib for the management of advanced medullary thyroid cancer: a real-world multicenter experience. Endocrinology and Metabolism202035587\u2013594. (https:\/\/doi.org\/10.3803\/EnM.2020.687)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/13\/1\/ETJ-23-0172.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/1\/ETJ-23-0172.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/1\/ETJ-23-0172.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:51:53Z","timestamp":1784555513000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/etj\/article\/2962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":42,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/etj-23-0172","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]}}}